Related Experiment Video
Updated: Jul 4, 2026

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
Published on: February 10, 2026
Contrast-induced nephropathy: the wheel has turned 360 degrees
H S Thomsen1, S K Morcos, B J Barrett
1Department of Diagnostic Radiology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Insights
Contrast-induced nephropathy (CIN) increases patient morbidity and mortality, especially in those with chronic kidney disease (CKD) and diabetes. Current effective strategies involve minimizing contrast dose, hydration, and avoiding repeat injections.
Area of Science:
- Nephrology
- Radiology
- Cardiology
Background:
- Contrast-induced nephropathy (CIN) is a significant complication associated with increased morbidity and mortality.
- CIN is particularly prevalent in patients with advanced chronic kidney disease (CKD) and diabetes mellitus.
- Despite numerous publications, effective CIN prevention strategies remain contentious and evolving.
Purpose of the Study:
- To review and summarize current understanding and management strategies for contrast-induced nephropathy (CIN).
- To highlight the association of CIN with chronic kidney disease (CKD) and diabetes.
- To discuss the limited number of high-quality randomized controlled trials in CIN research.
Main Methods:
- Review of over 900 publications on CIN from the past five years.
- Analysis of the limited proportion (<5%) of randomized prospective controlled studies.
- Evaluation of proposed methods to diminish CIN incidence, including contrast choice, pharmacologic manipulation, and volume expansion.
Main Results:
- The pathophysiology of CIN remains uncertain, with renal blood flow reduction and tubular cell toxicity implicated.
- Despite extensive research, significant changes in CIN management have been minimal.
- Established approaches remain the most effective for reducing CIN risk.
Conclusions:
- The most effective current approach to reduce CIN risk includes using the smallest effective dose of low- or iso-osmolar contrast media.
- Volume expansion, cessation of nephrotoxic drugs, and avoiding repeat contrast injections within 48 hours are crucial.
- Further high-quality randomized controlled studies are needed to advance CIN prevention and management.
Abstract:
Contrast-induced nephropathy (CIN) has been a hot topic during the last 5 years due its association with increased morbidity and mortality. CIN is an important complication, particularly in patients with advanced chronic kidney disease (CKD) associated with diabetes mellitus. Methods to diminish the incidence of CIN have been highly contentious. They include choice of contrast, pharmacologic manipulation, and volume expansion. The pathophysiology of this complication remains uncertain, but reduction in renal blood flow and direct toxicity of tubular cells has been implicated. More than 900 publications under the heading CIN have been published during the last 5 years. Fewer than 5% of these publications are randomized prospective controlled studies. In spite of the large number of reports on CIN, very little has been changed. The use of the smallest possible dose of low- or iso-osmolar contrast media, volume expansion, stopping nephrotoxic drugs, and avoiding repeat contrast injections within 48 hours remain the most effective approach to reduce the risk of CIN.
Related Concept Videos
Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Diabetic Nephropathy
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care

